{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:44:11Z","timestamp":1786977851328,"version":"build-2736575974"},"reference-count":63,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Depressive symptoms occur in several psychiatric disorders, often in the absence of a formal diagnosis of depression. We aimed to evaluate the efficacy and the tolerability of amisulpride, both alone and as augmentation therapy, in the treatment of depressive symptoms in individuals with any major psychiatric disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, PsycINFO, GreyLit, OpenGrey and ProQuest up to March 2020 for randomised controlled trials focussing on the treatment of an acute depressive episode in any major psychiatric disorder. A random\u2010effect meta\u2010analysis was performed to synthesize the findings on depressive symptoms (primary outcome), response rate and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We retrieved 11 studies including 2065 patients with a diagnosis of dysthymia (eight studies), major depression (one study) or schizophrenia (two studies). Amisulpride 50\u00a0mg\/day was associated with a larger reduction of depressive symptoms compared to placebo (standardised mean difference [SMD]\u00a0=\u00a0\u22120.70, CI 95% \u22120.92, \u22120.49;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00.0%), and was found to be comparable to selective serotonin reuptake inhibitors (SSRIs; SMD\u00a0=\u00a0\u22120.08, CI 95% \u22120.23, 0.06,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00.0%), amineptine, imipramine and amitriptyline in the treatment of dysthymia (three studies, not pooled). In individuals with schizophrenia, amisulpride administered at higher doses (&gt;400\u00a0mg\/day) was comparable to olanzapine and risperidone (two studies, not pooled). In terms of tolerability, amisulpride was superior to placebo for dysthymia (odds ratio [OR]\u00a0=\u00a03.94, CI 95% 1.07, 14.48;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00.0) and comparable with SSRIs (OR\u00a0=\u00a00.94, CI 95% 0.55, 1.62;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment with amisulpride could be a valid choice for selected individuals with dysthymia or depressive symptoms in the context of schizophrenia. More studies on the efficacy and tolerability of amisulpride are needed to draw firm conclusions on its potential benefits in other psychiatric disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hup.2801","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T05:40:22Z","timestamp":1622785222000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-0638","authenticated-orcid":false,"given":"Caroline","family":"Zangani","sequence":"first","affiliation":[{"name":"Oxford Health NHS Foundation Trust, Warneford Hospital  Oxford UK"},{"name":"Department of Psychiatry University of Oxford  Oxford UK"},{"name":"Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre  Oxford UK"},{"name":"Department of Health Sciences University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9262-079X","authenticated-orcid":false,"given":"Barbara","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-1752","authenticated-orcid":false,"given":"Hans\u2010Christian","family":"Stein","sequence":"additional","affiliation":[{"name":"Department of Health Sciences University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonora","sequence":"additional","affiliation":[{"name":"Department of Health Sciences University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2126-799X","authenticated-orcid":false,"given":"Armando","family":"D'Agostino","sequence":"additional","affiliation":[{"name":"Department of Health Sciences University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-0832","authenticated-orcid":false,"given":"Edoardo Giuseppe","family":"Ostinelli","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust, Warneford Hospital  Oxford UK"},{"name":"Department of Psychiatry University of Oxford  Oxford UK"},{"name":"Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-009-1521-8"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S29716"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200111000-00001"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(00)80007-3"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2375-1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(97)80113-0"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000026556"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-013-1688-3"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/11597130-000000000-00000"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-006-0101-4"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200201000-00004"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"issue":"8","key":"e_1_2_10_15_1","first-page":"519","article-title":"Subklinische depressie: Een klinisch relevante conditie? [Subclinical depression: A clinically relevant condition?]","volume":"50","author":"Cuijpers P.","year":"2008","journal-title":"Tijdschrift voor Psychiatrie"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11055-014-9896-3"},{"key":"e_1_2_10_17_1","first-page":"241","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Deeks J. J.","year":"2020"},{"key":"e_1_2_10_18_1","unstructured":"Drugs.com. (2020).https:\/\/www.drugs.com\/international\/amisulpride.html"},{"key":"e_1_2_10_19_1","unstructured":"European Medicines Agency. (2020).List of nationally authorised medicinal products. Retrieved fromhttps:\/\/www.ema.europa.eu\/documents\/psusa\/amisulpride\u2010list\u2010nationally\u2010authorised\u2010medicinal\u2010products\u2010psusa\/00000167\/202001_en.pdf"},{"key":"e_1_2_10_20_1","unstructured":"Food & Drug Administration. (2020).www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209510s000lbl.pdf"},{"key":"e_1_2_10_21_1","unstructured":"Generic Drugs. (2018).https:\/\/www.ndrugs.com\/?s=amisulpride"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.01.004"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1992.71.1.208"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820100061011"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.11.1411"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.180"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.07.005"},{"issue":"12","key":"e_1_2_10_28_1","first-page":"CD008121","article-title":"Second\u2010generation antipsychotics for major depressive disorder and dysthymia","author":"Komossa K.","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950050025003"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22236"},{"key":"e_1_2_10_31_1","first-page":"79","volume-title":"Progress in dopamine research in schizophrenia: A guide for physicians","author":"Lecrubier Y.","year":"2004"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(96)00103-6"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.07.022"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418130-00007"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153380"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"issue":"4","key":"e_1_2_10_37_1","first-page":"S9","article-title":"Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders","volume":"17","author":"Montgomery S. A.","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.13805"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61689-4"},{"key":"e_1_2_10_40_1","unstructured":"National Centres for Advancing Translational Sciences. (2020).https:\/\/drugs.ncats.io\/drug\/8110R61I4U"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpp.2181"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001040"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2013.765593"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.4103\/2249-4863.219992"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.11.1693"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988119901300307"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.24869\/psyd.2019.148"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00327-5"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(02)00188-9"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.320"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijlp.2017.10.003"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(97)00139-0"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2020.09.635"},{"key":"e_1_2_10_56_1","volume-title":"Stahl's essential psychopharmacology: Neuroscientific basis and practical applications","author":"Stahl S. M.","year":"2013"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1017\/9781108561402"},{"key":"e_1_2_10_58_1","volume-title":"Stata statistical software: Release 14","author":"StataCorp","year":"2015"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0194-7"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.01.060"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2006.09.003"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61729-2"}],"updated-by":[{"DOI":"10.1002\/hup.2831","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000}}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hup.2801","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:25:15Z","timestamp":1692973515000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/hup.2801"],"URL":"https:\/\/doi.org\/10.1002\/hup.2801","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"2021-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2801"}}